about
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy.Self-immolative nitrogen mustard prodrugs for suicide gene therapy.Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954.Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.Corrections to Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF)Virtual cofactors for an Escherichia coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2)Inhibition of human leukaemic thymidylate kinase and L1210 ribonucleotide reductase by dinucleotides of adenosine and thymidine and their phosphonate analogues
P50
Q33230876-69F6FC33-5B79-43D6-9FE9-90953649A985Q33333874-AE448184-54CB-4045-B928-25FE1CB2C896Q34207363-605520EE-63BE-4744-8142-2F225805ED91Q34978580-BC784837-0C41-4A16-86FF-FE44D1A87149Q39200670-58029B85-BE27-44A7-9258-1727F6F928B4Q39732826-9D695850-D017-4257-B990-A6B662CAD66EQ39741030-B1D3D888-F745-450F-8F60-FABB44FAC206Q39867959-4A4E2750-64DA-480D-BDE3-D573BD8AA9AEQ39966345-6F393292-1E98-4318-8892-68B75E4E1733Q40987548-D4ACCB2D-2215-4759-A6AA-FB150D0BDDA9Q41529502-8BC2A455-E7C8-4F3E-8BB3-AC50AF8AF7E5Q42992425-EE893237-EAE5-4268-B0E5-A020B0EFE7ECQ45994705-C812F929-CDDA-49F8-93F5-F27E72A7E077Q57727172-5B9E005F-A46E-45F8-8A0E-7144DC1706A6Q57727190-1335A5D0-9BE5-4D4E-94B4-0DFF41C2FD99Q57727194-97C47BBE-78D3-43C1-A6C6-725C14A47BD7Q57727199-49DCC9D5-C7BF-4F02-8D0B-18F77F8C7314
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lawrence C Davies
@nl
Lawrence C Davies
@sl
Lawrence C. Davies
@en
Lawrence C. Davies
@es
type
label
Lawrence C Davies
@nl
Lawrence C Davies
@sl
Lawrence C. Davies
@en
Lawrence C. Davies
@es
prefLabel
Lawrence C Davies
@nl
Lawrence C Davies
@sl
Lawrence C. Davies
@en
Lawrence C. Davies
@es
P106
P1153
35588317300
P31
P496
0000-0002-0451-8670